OSTEOGENEX, INC

Basic Information

PO Box 3132
Kansas city, KS, 66103-

Company Profile

n/a

Additional Details

Field Value
DUNS: 167266555
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: n/a


  1. Oral delivered bone building therapy for osteoporosis

    Amount: $475,076.00

    DESCRIPTION (provided by applicant): The osteoporosis market is still in demand for new therapeutics due to the lack of safe orally available bone building drugs. Currently, parathyroid hormone (PTH; ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Anabolic Therapeutics for Increasing Bone Denisty and Quality

    Amount: $994,943.00

    DESCRIPTION (provided by applicant): OsteoGeneX is developing a therapeutic directed against the new bone target Sclerostin (SOST) for the treatment of osteoporosis and related bone disorders. Throug ...

    SBIR Phase II 2008 Department of Health and Human Services
  3. Therapeutics for increasing Bone Density and Quality

    Amount: $133,904.00

    DESCRIPTION (provided by applicant): Osteoporosis affects 55% of Americans over the age of 50, and incurs a medical cost of $47 million a day. It is caused by a disruption in the fine equilibrium betw ...

    SBIR Phase I 2006 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government